# A Study of rhGAA in Patients With Late-Onset Pompe Disease

> **NCT00250939** · PHASE2 · COMPLETED · sponsor: **Genzyme, a Sanofi Company** · enrollment: 5 (actual)

## Conditions studied

- Pompe Disease (Late-onset)
- Glycogen Storage Disease Type II (GSD-II)
- Acid Maltase Deficiency Disease
- Glycogenosis 2

## Interventions

- **BIOLOGICAL:** Myozyme

## Key facts

- **NCT ID:** NCT00250939
- **Lead sponsor:** Genzyme, a Sanofi Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-02
- **Primary completion:** 2006-07
- **Final completion:** 2006-11
- **Target enrollment:** 5 (ACTUAL)
- **Last updated:** 2014-02-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00250939

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00250939, "A Study of rhGAA in Patients With Late-Onset Pompe Disease". Retrieved via AI Analytics 2026-09-09 from https://api.ai-analytics.org/clinical/NCT00250939. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*